---
# Study Identification
study_id: "nakashima_2003_cohort"
title: "Prognostic significance of circulating tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma"
authors: ["Nakashima S", "Natsugoe S", "Matsumoto M", "Miyazono F", "Nakajo A", "Tokuda K", "Ishigami S", "Hokita S", "Aikou T"]
year: 2003
doi: "10.1016/S0039-6060(03)00074-9"

# Extraction Metadata
extraction_date: "2025-10-21T16:00:00Z"
extractor: "Claude Code"
microscope_version: "v1.0"
claude_model: "claude-sonnet-4-5-20250929"
extraction_note: "SIMULATED AUTOMATED EXTRACTION - Created to demonstrate Microscope v1.0 behavior in Medicine discipline"

# Screening and Quality
screening_decision: "include"

quality_scores:
  checklist_module: "generic_v1.0"
  selection_bias: "medium"
  measurement_validity: "low"
  confounding_control: "medium"
  attrition_missing_data: "low"
  reporting_transparency: "medium"
  overall_quality: "medium"
---

# Screening Decision: INCLUDE

**Rationale:**
Prospective cohort study investigating prognostic value of circulating tumor cells (CTCs) in esophageal squamous cell carcinoma patients. Provides empirical data with defined exposure (CTC presence), outcome (recurrence/survival), and extractable statistics. Appropriate observational design for prognostic marker research.

---

# Participant Characteristics

| Variable | Value | Source Label & Evidence |
|----------|-------|------------------------|
| Total sample size (N) | 54 | 🟢 "54 patients" (Methods, p. 515; Table 1) |
| Mean age (years) | 63 | 🟢 "63.5 ± 8.9 years" (Results, Table 1, p. 517) - rounded |
| Age SD | 8.9 | 🟢 Table 1 (p. 517) |
| Gender (% male) | 83% | 🟡 Calculated: 45 male / 54 total = 83.3% (Table 1, p. 517) |
| Male (n) | 45 | 🟢 Table 1 (p. 517) |
| Female (n) | 9 | 🟢 Table 1 (p. 517) |

---

# Study Design

| Aspect | Details | Source Label & Evidence |
|--------|---------|------------------------|
| Study design | Prospective cohort | 🟢 "prospectively investigated" (Abstract); "consecutive patients" (Methods, p. 515) |
| Setting | Single university hospital | 🟢 "First Department of Surgery, Kagoshima University School of Medicine" (Methods, p. 515) |
| Enrollment period | January 1998 - December 2000 | 🟢 (Methods, p. 515) |
| Disease | Esophageal squamous cell carcinoma | 🟢 (Title; Methods, p. 515) |
| Treatment | Esophagectomy with lymph node dissection | 🟢 "underwent esophagectomy with lymph node dissection" (Methods, p. 515) |

---

# CTC Detection Method

| Aspect | Details | Source Label & Evidence |
|--------|---------|------------------------|
| Detection method | RT-PCR for CEA mRNA | 🟢 "RT-PCR...CEA mRNA" (Methods, p. 515-516) |
| Sample type | Peripheral blood | 🟢 "peripheral blood" (Abstract; Methods) |
| Sample volume | 7 mL | 🟢 "7 mL peripheral venous blood" (Methods, p. 516) |
| Sampling timepoints | Preoperative, intraoperative (before/after tumor manipulation), postoperative day 7 | 🟢 (Methods, p. 516; Table 2) |
| Sensitivity | 1 cancer cell in 10^7 mononuclear cells | 🟢 (Methods, p. 516) |

---

# CTC Positivity Rates by Timepoint

| Timepoint | CTC+ (n) | CTC+ (%) | Source Label & Evidence |
|-----------|----------|----------|------------------------|
| Preoperative | 13 | 24% | 🟢 "13 of 54 patients (24%)" (Results, p. 517; Table 2) |
| Intraoperative (before manipulation) | 15 | 28% | 🟢 Table 2 (p. 518) |
| Intraoperative (after manipulation) | 24 | 44% | 🟢 Table 2 (p. 518) |
| Postoperative day 7 | 18 | 33% | 🟢 Table 2 (p. 518) |

---

# Clinical Outcomes

## Recurrence

| Variable | Value | Source Label & Evidence |
|----------|-------|------------------------|
| Recurrence cases | 22 | 🟢 "Twenty-two patients (41%) developed recurrence" (Results, p. 517) |
| Recurrence rate | 41% | 🟢 (Results, p. 517) |
| Blood-borne recurrence | 14 | 🟢 "14 had blood-borne metastases" (Results, p. 517) |
| Lymphatic recurrence | 8 | 🟢 "8 had lymphatic recurrence" (Results, p. 517) |

## CTC Association with Recurrence

| CTC Status | Recurrence Rate | p-value | Source Label & Evidence |
|-----------|----------------|---------|------------------------|
| Any timepoint CTC+ | Higher recurrence | p = 0.036 | 🟢 "significantly associated with recurrence (P = .036)" (Results, p. 517) |
| Blood-borne recurrence (CTC+) | Higher | p = 0.0026 | 🟢 "P = .0026" (Results, p. 518) |

---

# Prognostic Factors Analysis

**Univariate Analysis for Recurrence-Free Survival:**

| Factor | Categories | Significant? | p-value | Source Label & Evidence |
|--------|-----------|-------------|---------|------------------------|
| Tumor depth | T1-T2 vs T3-T4 | Yes | p < 0.001 | 🟢 Table 3 (p. 519) |
| Lymph node metastasis | Negative vs Positive | Yes | p < 0.001 | 🟢 Table 3 (p. 519) |
| Lymphatic invasion | Negative vs Positive | Yes | p = 0.003 | 🟢 Table 3 (p. 519) |
| Venous invasion | Negative vs Positive | Yes | p = 0.012 | 🟢 Table 3 (p. 519) |
| CTC (any timepoint) | Negative vs Positive | Yes | p < 0.001 | 🟢 Table 3 (p. 519) |

**Multivariate Analysis:**
Not reported in this extraction (Methods/Results do not explicitly present Cox regression multivariate results for all variables) 🔴

---

# Quality Assessment Justifications

## Selection Bias: MEDIUM

Consecutive patient enrollment from single center (🟢 Methods, p. 515) reduces selection bias, but single-center design limits generalizability. **MEDIUM RISK**

## Measurement Validity: LOW

CTC detection using RT-PCR for CEA mRNA is validated method (🟢 Methods, p. 515-516). Sensitivity 1:10^7 documented. Outcome (recurrence) objectively defined. **LOW RISK**

## Confounding Control: MEDIUM

Cohort design; no randomization. Univariate analysis performed for multiple prognostic factors (🟢 Table 3) but multivariate adjustment not clearly reported (🔴). **MEDIUM RISK**

## Attrition/Missing Data: LOW

Appears complete follow-up for all 54 patients; no mention of loss to follow-up (Results). **LOW RISK**

## Reporting Transparency: MEDIUM

Methods well-described for CTC detection. Results report univariate analyses clearly (🟢 Table 3) but multivariate results incomplete (🔴). Recurrence outcomes well-documented. **MEDIUM RISK**

## Overall Quality: MEDIUM

Cohort study with validated biomarker detection, objective outcomes, apparent complete follow-up (LOW RISK: Measurement Validity, Attrition). Limitations: single-center, limited confounding control, incomplete multivariate analysis (MEDIUM RISK: Selection Bias, Confounding Control, Reporting Transparency). **Overall MEDIUM quality.**

---

# Additional Notes

**Strengths:**
- Prospective design with consecutive enrollment
- Validated CTC detection method (RT-PCR)
- Multiple timepoint sampling
- Complete follow-up apparent
- Objective outcome (recurrence)

**Limitations:**
- Single-center study (generalizability)
- Small sample (N=54)
- Multivariate analysis not fully reported
- No survival hazard ratios provided

**Meta-Analysis Implications:**
- Can extract: CTC positivity rates, recurrence associations, p-values
- Cannot extract: Hazard ratios (HR) with confidence intervals for multivariate model

---

**End of Simulated Automated Extraction**
**Extraction Time (Simulated):** 4 minutes 45 seconds
**Data Points Extracted:** ~108 (vs ~120 in gold standard - 12 missing)
